Similar data were generated using an in vivo priming model and B16-OVA tumor challenge in which wild-type mice were injected with naïve OT-I CD8+ T cells (CD45.2+) and OVA-presenting activated bone marrow-derived dendritic cells that were either wild type or PD-L1 deficient. Here, CD8A is linked to neoplasm.